SCHEDULE: FMR LLC Discloses 5.4% Stake in Nurix Therapeutics

FMR LLC, through its affiliates, has reported beneficial ownership of 5.4% of Nurix Therapeutics Inc.'s common stock as of March 31, 2026.

Summary

• FMR LLC, along with its affiliates and related entities, has filed a Schedule 13G indicating beneficial ownership of 5,541,271.11 shares of Nurix Therapeutics Inc. common stock.
• This holding represents approximately 5.4% of the total outstanding common stock of Nurix Therapeutics Inc.
• The filing date for this report is March 31, 2026, with the report itself filed on May 5, 2026.
• The reporting entities include FMR LLC, FIAM LLC, Fidelity Institutional Asset Management Trust Company, Fidelity Management & Research Company LLC, Fidelity Management Trust Company, and Strategic Advisers LLC.
• Abigail P. Johnson, a significant owner of FMR LLC, is also noted in the filing.
• The filing asserts that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership by an institutional investor and does not contain operational or financial performance data for the company itself.

Positives

• FMR LLC, a significant institutional investor, has disclosed a substantial ownership stake, which could be interpreted as a positive signal of confidence in Nurix Therapeutics' long-term prospects.
• The filing indicates that the shares were acquired and are held in the ordinary course of business, suggesting a stable, long-term investment approach rather than a short-term activist play.

Negatives

• The filing does not contain any negative financial results or operational challenges for Nurix Therapeutics; it is purely an ownership disclosure.

Risks

• While not explicitly stated as risks within this filing, any significant change in ownership by a major institutional investor like FMR LLC could potentially influence market perception and stock price volatility.
• The filing mentions that other persons have the right to receive or the power to direct dividends or proceeds from the sale of the common stock, but no single other person's interest exceeds five percent, mitigating concentrated risk from external parties.

Future Outlook

This filing is a disclosure of current ownership and does not contain forward-looking statements or guidance from Nurix Therapeutics Inc. itself.

Management Comments

• "This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the 'FMR Reporters')."
• "This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters..."
• "The undersigned persons, on May 5, 2026, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of NURIX THERAPEUTICS INC at March 31, 2026."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect..."

Industry Context

StockSavvy.ai notes that the disclosure of a significant stake by FMR LLC, a major investment management firm, in Nurix Therapeutics, a company in the emerging field of targeted protein degradation for drug discovery, suggests continued institutional interest in the biotechnology sector's innovative therapeutic approaches.

Stakeholder Impact

• Shareholders: The disclosure may influence investor sentiment due to the significant stake held by a major institutional investor, potentially impacting trading activity.
• Management of Nurix Therapeutics: The presence of a large institutional holder like FMR LLC can provide a stable shareholder base and potentially influence corporate governance discussions.
• FMR LLC Clients: Clients invested in FMR LLC funds benefit from the firm's active management and strategic investments in companies like Nurix Therapeutics.

Next Steps

• FMR LLC will continue to monitor its beneficial ownership of Nurix Therapeutics Inc. common stock and will file amendments to this Schedule 13G as required by SEC regulations.
• Nurix Therapeutics Inc. will continue its operations and drug development programs.

Key Dates

Keywords

Nurix Therapeutics, FMR LLC, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Biotechnology, Pharmaceuticals